

DESIGNED FOR

inhale ABILITY



in*hale*a*bil*it*y

/in'hāl'ə'bilədē/

“Having characteristics that allow respirable particles to follow the inhaled airstream deep into the lung.”

The ASERVO EQUIHALER is designed for inhaleABILITY for the management of severe equine asthma.

If clinical signs do not improve or worsen despite administration of ASERVO EQUIHALER, the prescriber should consider additional diagnostic evaluation.

Designed to consistently deliver ciclesonide



✓	Soft Mist™ Technology delivers medication in a slow-moving mist ¹
✓	Prodrug activated in the airway epithelium ²
✓	Activated prodrug has 12 times greater glucocorticoid receptor affinity than dexamethasone ²
✓	No statistically significant decrease in serum cortisol ^{3,4}
✓	Accepted by >93% of horses ⁵
✓	Proven safety and efficacy under controlled and field conditions in over 600 horses* ^{3,5,6}

* Treated with ASERVO EQUIHALER or placebo.

In a large clinical field study, the most common adverse reactions reported were coughing, nasal discharge, sneezing, and nasal irritation/bleeding.

1. Dalby, R., Spallek, M. and Voshaar, T., 2004. A review of the development of Respimat® Soft Mist™ Inhaler. *International journal of pharmaceuticals*, 283(1-2), pp.1-9.
2. Mukker, J.K., Singh, R.S.P. and Derendorf, H., 2016. Ciclesonide: a pro-soft drug approach for mitigation of side effects of inhaled corticosteroids. *Journal of pharmaceutical sciences*, 105(9), pp.2509-2514.
3. Lavoie, J.P., Bullone, M., Rodrigues, N., Germim, P., Albrecht, B. and von Salis Soglio, M., 2019. Effect of different doses of inhaled ciclesonide on lung function, clinical signs related to airflow limitation and serum cortisol levels in horses with experimentally induced mild to severe airway obstruction. *Equine veterinary journal*.
4. Derom, E., Van De Velde, V., Marissens, S., Engelstätter, R., Vincken, W. and Pauwels, R., 2005. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5' monophosphate in asthmatic patients. *Pulmonary pharmacology & therapeutics*, 18(5), pp.328-336.
5. Prescribing Information. Aservo® EquiHaler® (ciclesonide inhalation spray), 343 mcg/actuation, glucocorticoid
6. Freedom of Information Summary. 2020. Original New Drug Animal Application. Aservo® EquiHaler® (ciclesonide inhalation spray)